CN113549018B - Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application - Google Patents

Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application Download PDF

Info

Publication number
CN113549018B
CN113549018B CN202010329894.4A CN202010329894A CN113549018B CN 113549018 B CN113549018 B CN 113549018B CN 202010329894 A CN202010329894 A CN 202010329894A CN 113549018 B CN113549018 B CN 113549018B
Authority
CN
China
Prior art keywords
pyrimidin
methyl
isopropyl
quinazolin
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010329894.4A
Other languages
Chinese (zh)
Other versions
CN113549018A (en
Inventor
陆涛
陈亚东
黄健航
王信人
李红玫
董瑞楠
刘萧悦
万春阳
唐伟方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202010329894.4A priority Critical patent/CN113549018B/en
Publication of CN113549018A publication Critical patent/CN113549018A/en
Application granted granted Critical
Publication of CN113549018B publication Critical patent/CN113549018B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

The invention discloses a protein kinase inhibitor and derivatives thereof, a preparation method, a pharmaceutical composition and application. The structure of the compound of the protein kinase inhibitor is shown as a formula (I), and the protein kinase inhibitor derivative relates to an isomer, a diastereoisomer, an enantiomer, a tautomer, a solvate and a solvent of the protein kinase inhibitorThe salt of the compound, pharmaceutically acceptable salt or mixture thereof has high-efficiency inhibition effect on protein kinase, can reduce or inhibit the activity of protein kinase in cells, can be used for preparing medicines for treating and/or preventing hyperproliferative diseases, virus-induced infectious diseases and/or cardiovascular diseases, and has simple synthesis method and easy operation.

Description

Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application
Technical Field
The invention relates to a protein kinase inhibitor and a derivative thereof, a preparation method, a pharmaceutical composition and application thereof, in particular to a protein kinase inhibitor and a derivative thereof which can be prepared into medicines for treating and/or preventing hyperproliferative diseases such as cancers, virus-induced infectious diseases and/or cardiovascular diseases, a preparation method, a pharmaceutical composition and application thereof.
Background
Protein kinase is widely existed in human body and plays an important physiological function, and when abnormal regulation or mutation occurs in protein kinase, hyperproliferative diseases, cardiovascular and cerebrovascular diseases, diabetes, inflammation and immune system diseases are often caused.
Cyclin-dependent kinases (CDKs) are an important class of serine/threonine protein kinases that bind to cyclin (cyclin) to form dimeric complexes that act as modulators, including catalytic phosphorylation of corresponding downstream substrates, driving processes of the cell cycle, and sequentially completing DNA synthesis and mitosis, leading to cell growth and proliferation. Among them, CDK9 plays an important role in transcription of intracellular genetic information as a cyclin-dependent kinase. The complex formed by CDK9 and cyclin T1, T2a, T2b or K is positive transcription elongation factor (P-TEFb); when negative transcription elongation factors such as NELF and DSIF participate in negative regulation of cell transcription, transcription is inhibited in an initial complex stage, and P-TEFb is recruited to a system of NELF and DSIF for inhibiting transcription elongation, and acts on a C-terminal domain Ser-2 of a large subunit II (RNA polymerase II) of phosphorylating RNA polymerase to release the negative transcription elongation factors from the transcription complex, thereby promoting continuous transcription. In many malignant cells, cell cycle regulation and transcription abnormalities result from the high activation of CDK protein kinases.
Aberrant activation of CDK9 activity in P-TEFb heterodimers is primarily associated with hyperproliferative diseases (e.g., cancer), virus-induced infectious diseases, or cardiovascular diseases. Biopsy results isolated from chronic lymphocytic leukemia or multiple myeloma patients revealed that overactive CDK9 pathway could increase the expression of anti-apoptotic proteins such as Mcl-1, thereby inhibiting normal apoptosis of cells. In addition, in other malignancies such as lymphomas, neuroblastomas, primary neuroectodermal tumors, rhabdomyosarcomas, and prostate cancers, there are CDK 9-mediated abnormalities in the expression of related pathway genes or protein levels, and these abnormalities are all associated with CDK9 being involved in the expression of anti-apoptotic factors and in the proliferation process of tumor cells.
Disclosure of Invention
The invention aims to: the first object of the invention is to provide a protein kinase inhibitor and a derivative thereof, the second object is to provide a preparation method of the protein kinase inhibitor and the derivative thereof, the third object is to provide a pharmaceutical composition containing the protein kinase inhibitor and the derivative thereof, and the fourth object is to provide the application of the protein kinase inhibitor and the derivative thereof in preparing medicines for treating and/or preventing hyperproliferative diseases such as cancers, virus-induced infectious diseases and/or cardiovascular diseases.
The technical scheme is as follows: the protein kinase inhibitor and the derivative thereof have the structure shown in the formula (I), wherein the derivative is an isomer, a diastereoisomer, an enantiomer, a tautomer, a solvate, a salt of the solvate, a pharmaceutically acceptable salt or a mixture of the isomers and the diastereoisomer, the enantiomer, the tautomer, the solvate and the salt of the solvate of the compound:
wherein:
v, W, X, Y or Z is CR 4 Or a nitrogen atom;
R 1 is thatOr->
R 2 Is hydrogen atom, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy or Het 1 Substituents, wherein C 1 -C 6 Alkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy, het 1 Substituted by one or more halogen, hydroxy, amino, hetero atoms, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy or Het 1 Substitution; het 1 Substituents are morpholinyl, morpholinylalkyl, morpholinylalkoxy, morpholinylalkylamino, piperazinyl, piperazinylalkyl, piperazinylalkylamino, homopiperazinyl, homopiperazinylalkyl, homopiperazinylalkoxy, homopiperazinylalkylamino, piperidinyl, piperidinylalkyl, piperidinylalkoxy, piperidinylalkylamino, tetrakisA hydropyrrolyl, tetrahydropyrrolylalkyl, tetrahydropyrrolylalkoxy, tetrahydropyrrolylalkylamino, tetrahydrofuranyl, tetrahydrofuranalkyl, tetrahydrofuranalkoxy, tetrahydrofuranalkylamino, tetrahydropyranyl, tetrahydropyranoxy or tetrahydropyranyl group;
R 3 is hydrogen atom, halogen, C 1 -C 6 Alkyl or cyano;
R 4 is hydrogen atom, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy or cyano;
R 5 hydrogen atom, halogen, nitro, C substituted in any position on the aromatic ring 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylamino or phenoxy, wherein C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy or C 1 -C 6 Alkylamino is substituted with 1-3 halogens, C 1 -C 6 Alkyl, C 3 -C 7 Cycloalkyl, heterocyclyl, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, at least 1 halogen-substituted phenyl, at least 1 halogen-substituted heteroaryl or Het 1 Substitution;
R 6 or R is 7 Is one or more hydrogen atoms, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy or C 1 -C 3 An alkylamino group;
q is an oxygen atom or an imino group.
Preferably, the protein kinase inhibitor and its derivative structure are as follows:
v is a nitrogen atom;
R 2 is hydrogen atom, C 1 -C 6 Alkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy or Het 1 Substituents, wherein C 1 -C 6 Alkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy, het 1 Substituted by one or more fluorine atoms, hetero atoms, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylamino, C 1 -C 6 Alkoxy or Het 1 Substitution; het 1 Substituents are morpholinyl, morpholinylalkyl, morpholinylalkoxy, morpholinylalkylamino, piperazinyl, piperazinylalkyl, piperazinylalkoxy, piperazinylalkylamino, homopiperazinyl, homopiperazinylalkyl, homopiperazinylalkoxy, homopiperazinylalkylamino, piperidinyl, piperidinylalkyl, piperidinylalkoxy, piperidinylalkylamino, tetrahydropyrrolyl, tetrahydropyrrolylalkyl, tetrahydropyrrolylalkoxy, tetrahydropyrrolylalkylamino, tetrahydrofuranyl, tetrahydrofuranalkyl, tetrahydrofuranalkoxy, tetrahydrofuranylamino, tetrahydropyranyl, tetrahydropyranoxy or tetrahydropyran alkylamino;
R 3 is a hydrogen atom, a fluorine atom, a chlorine atom, a cyano group or C 1 -C 6 An alkyl group;
R 4 is hydrogen atom, fluorine atom, C 1 -C 3 Alkyl or C 1 -C 3 An alkoxy group;
R 5 hydrogen atom substituted at any position on aromatic ring, fluorine atom, nitro group, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylamino, phenoxy, wherein C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy or C 1 -C 6 Alkylamino is substituted with 1-3 fluorine atoms, C 1 -C 6 Alkyl, C 3 -C 7 Cycloalkyl, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, phenyl substituted with 1-2 fluorine atoms, heteroaryl substituted with 1-2 fluorine atoms, piperazinyl or morpholinyl;
R 6 or R is 7 Is one or more hydrogen atoms, fluorine atoms, C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy or C 1 -C 3 An alkylamino group.
Preferably, the protein kinase inhibitor and derivatives thereof have the structure of formula (II):
wherein:
R 1 is thatOr->
R 2 Is hydrogen atom, methyl, morpholin-4-yl, piperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4- (2-methoxyethyl) piperazinyl, homopiperazinyl, N-methylpiperazinyl, thiomorpholin-4-yl, piperidinyl, 4- (N, N-dimethylpiperazinyl, (N-methylpiperazin-4-yl) piperidinyl, 3-methylaminopyrrolidinyl, (morpholin-4-yl) methyl, (piperazin-1-yl) methyl, (4-methylpiperazin-1-yl) methyl, (N-methylpiperazin-1-yl) methyl, (tetrahydropyran-4-yl) amino, (tetrahydrofuran-3-yl) amino, (N-methylpiperidin-4-yl) amino, 2- (dimethylamino) ethylamino, 2-methoxyethylamino, 3-methoxypropylamino, 2, 5-diazabicyclo [2.2.1]Heptyl-2-yl, 4-methylpiperazin-3-one, (S) -3-methylpiperazin, (R) -3-methylpiperazin, (8-azabicyclo [ 3.2.1)]Octan-3-yl) amino, (R) -2-methylpiperazinyl, (S) -2-methylpiperazinyl, pyrrolidinyl, (2-methoxyethyl) amino, (3-methoxypropyl) amino, (tetrahydropyran-4-yl) amino, (tetrahydrofuran-3-yl) amino, N-dimethylamino, azido or 4, 4-difluoropiperidinyl;
R 3 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group or a cyano group;
R 4 is a hydrogen atom, a fluorine atom, a methyl group or a methoxy group;
R 5 is hydrogen atom, fluorine atom, nitro group, methyl group, trifluoromethyl group, ethyl group, methoxy group, difluoromethoxy group, trifluoromethoxy group, methylamino group, dimethylamino group, ethoxy group, butoxy group, isopropoxy group, isobutoxy group, 1-cyclopropylmethoxy group, 1-cyclopentylmethoxy group, 1-cyclohexylmethoxy group, phenoxy group, benzyloxy group, 1-phenylethoxy group, 4-fluoro groupBenzyloxy, 2, 4-difluorobenzyloxy, benzylamino, 3- (4-methylpiperazin-1-yl) propoxy, 3-morpholin-1-ylpropoxy, but-2-en-1-yloxy, but-2-yn-1-yloxy, 1- (pyridin-4-yl) methoxy;
R 6 、R 7 is one or more hydrogen atoms, fluorine atoms, C 1 -C 3 Alkyl, methoxy or methylamino;
q is an oxygen atom or an imino group.
Further preferably, the protein kinase inhibitor and its derivative structure:
R 1 is phenyl, 2-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-ethoxyphenyl, 4-fluoro-2-ethoxyphenyl, 2-benzyloxyphenyl, 4-fluoro-2-benzyloxyphenyl, 3-isopropyl-2-methyl-2H-indazol-5-yl, 7-fluoro-3-isopropyl-2-methyl-2H-indazol-5-yl, 1-isopropyl-2-methyl-1H-benzo [ d ]]Imidazol-6-yl, 4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ]]Imidazol-6-yl, 1-methyl-1H-indol-3-yl, 1-methyl-1H-benzo [ d ]][1,2,3]Triazol-6-yl or 1-isopropyl-1H-benzo [ d ]][1,2,3]Triazol-6-yl;
R 2 is hydrogen atom, morpholin-4-yl, piperazinyl, piperidinyl, 4-methylpiperazinyl, homopiperazinyl, N-methylpiperazinyl, 4-ethylpiperazinyl, (piperidin-4-yl) amino, (1-methylpiperidin-4-yl) amino, 2, 5-diazabicyclo [2.2.1]Heptyl-2-yl, (2-aminoethyl) amino, (2- (methylamino) ethyl) amino, (2- (dimethylamino) ethyl) (methyl) amino, (3-methoxyethyl) amino, (3-methoxypropyl) amino, 4-methylpiperazin-2-one, 4-methylpiperazin-3-one, (S) -3-methylpiperazin-yl, (R) -2-methylpiperazin-yl, (S) -2-methylpiperazin-yl, (8-azabicyclo [ 3.2.1)]Octane-3-yl) amino, pyrrolidinyl, (2-methoxyethyl) amino, (3-methoxypropyl) amino, (tetrahydropyran-4-yl) amino, (tetrahydrofuran-3-yl) amino, N-dimethylamino, azido or 4, 4-difluoropiperidinyl.
Preferably, the protein kinase inhibitor is any one of the following compounds:
4- (4-methylpiperazin-1-yl) -N- (4-phenylpyrimidin-2-yl) quinazolin-7-amine (I-1),
n- (4- (2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-2),
n- (4- (4-fluoro-2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-3),
n- (5-fluoro-4- (4-fluoro-2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-4),
n- (4- (2-ethoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-5),
n- (4- (2-ethoxy-4-fluorophenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-6),
n- (4- (2- (benzyloxy) phenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-7),
n- (4- (2- (benzyloxy) -4-fluorophenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-8),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-9),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4-morpholinylquinazolin-7-amine (I-10),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (piperazin-1-yl) quinazolin-7-amine (I-11),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-12),
4- (4-ethylpiperazin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-13),
4- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -1-methylpiperazin-2-one (I-14),
1- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -4-methylpiperazin-2-one (I-15),
(S) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (3-methylpiperazin-1-yl) quinazolin-7-amine (I-16),
(R) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (3-methylpiperazin-1-yl) quinazolin-7-amine (I-17),
(R) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (2-methylpiperazin-1-yl) quinazolin-7-amine (I-18),
(S) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (2-methylpiperazin-1-yl) quinazolin-7-amine (I-19),
4- (1, 4-homopiperazin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-20),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (4-methyl-1, 4-homopiperazin-1-yl) quinazolin-7-amine (I-21),
4- (2, 5-diazabicyclo [2.2.1] hept-2-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-22),
N 4 - (8-azabicyclo [ 3.2.1)]Octane-3-yl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-23),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (piperidin-4-yl) quinazoline-4, 7-diamine (I-24),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (1-methylpiperidin-4-yl) quinazoline-4, 7-diamine (I-25),
N 4 - (2- (dimethylamino) ethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-26),
N 4 - (2-aminoethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-27),
N 4 - (2- (dimethylamino) ethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 Methyl quinazoline-4, 7-diamine (I-28),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (2- (methylamino) ethyl) quinazolinesThe 4, 7-diamine (I-29),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (2-methoxyethyl) quinazoline-4, 7-diamine (I-30),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (3-methoxypropyl) quinazoline-4, 7-diamine (I-31),
5- (7- (((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -2, 5-diazabicyclo [2.2.1] heptane-2-carboxylic acid ester (I-32),
n- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-33),
n- (4- (4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-34),
n- (5-fluoro-4- (4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-35),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (tetrahydrofuran-3-yl) quinazolin-4, 7-diamine (I-36),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (tetrahydro-2H-pyran-4-yl) quinazoline-4, 7-diamine (I-37),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 ,N 4 Dimethylquinazoline-4, 7-diamine (I-38),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -2-methyl-4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-39),
4- (azido-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-40),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (piperidin-1-yl) quinazolin-7-amine (I-41),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (pyrrolidin-1-yl) quinazolin-7-amine (I-42),
1- (4- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) piperazin-1-yl) ethanone (I-43),
4- (4, 4-difluoropiperidin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-44),
n- (4- (1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-45),
n- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-46),
N 4 - (2-methoxyphenyl) -N 2 - (4- (4-methylpiperazin-1-yl) quinazolin-7-yl) pyrimidine-2, 4-diamine (I-47),
n- (4- (2-methoxyphenoxy) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-48),
n- (4- (1-isopropyl-1H-benzo [ d ] [1,2,3] triazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-49),
n- (4- (1-methyl-1H-benzo [ d ] [1,2,3] triazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-50).
Preferably, the pharmaceutically acceptable salt is a salt of the protein kinase inhibitor with an acid or a base, the acid being hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid, the base being an inorganic base containing a basic metal cation, alkaline earth metal cation or ammonium cation salt.
The preparation method of the protein kinase inhibitor and the derivative thereof is characterized by comprising the following steps:
the bromo-compound A0 is firstly converted into the pinacol borate A1 and then the coupling reaction is carried out to obtain the compound A, or the bromo-compound A0 is directly coupled to obtain the compound A; the compound B1 is alkylated to introduce R 2 Obtaining a compound B; the compound A and the compound B are obtained through alkylation reactionTo obtain the compound (I);
therein, W, V, X, Y, Z, R 1 、R 2 、R 3 Is as defined in any one of claims 1 to 4;
adding the corresponding acid or alkali solution into the solution of the compound (I) prepared by the method, and removing the solvent under reduced pressure after complete salification to obtain the pharmaceutically acceptable salt of the protein kinase inhibitor.
The pharmaceutical composition of the invention comprises the protein kinase inhibitor and/or a derivative thereof and a pharmaceutically acceptable carrier.
The protein kinase inhibitor and the derivatives thereof can be added with pharmaceutically acceptable carriers to prepare common medicinal preparations such as tablets, capsules, syrup, suspending agents and injection, and can be added with common medicinal auxiliary materials such as spice, sweetener, liquid or solid filler or diluent and the like.
The protein kinase inhibitor and the application of the derivative thereof in preparing medicines for treating and/or preventing hyperproliferative diseases, virus-induced infectious diseases and/or cardiovascular diseases.
Preferably, the hyperproliferative disease is lung cancer, prostate cancer, cervical cancer, colorectal cancer, melanoma, ovarian cancer, breast cancer, renal cancer, a tumor of the nervous system, lymphoma or leukemia.
The protein kinase inhibitor and the derivative thereof can be prepared into medicines for treating and/or preventing acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, burkitt's lymphoma (Burkitt's lymphoma), follicular lymphoma, breast cancer, non-small cell lung cancer, melanoma, renal cancer, ovarian cancer, prostate cancer, colon cancer or central nervous system tumor.
The beneficial effects are that: compared with the prior art, the invention has the following remarkable advantages:
(1) The protein kinase inhibitor, the derivative and the pharmaceutical composition thereof can effectively inhibit CDK9 kinase activity, and CDK9 kinase inhibits IC 50 Values of no more than 1. Mu.M, most preferably no more than 0.1. Mu.M, can reach nanomolar concentration levels; can also inhibit proliferation of MV4-11 tumor cells, and inhibit proliferation of MV4-11 tumor cells 50 Values of most not more than 1. Mu.M, most preferably not more than 0.1. Mu.M; and has inhibiting effect on various tumor cells, and various tumor cells inhibit IC 50 Values of no more than 1 mu M are adopted, and the nanomolar concentration level can be optimally achieved; the application is wide, and the medicine can be prepared into medicines for treating and/or preventing hyperproliferative diseases, virus-induced infectious diseases and/or cardiovascular diseases;
(2) The medicine has wide application, and can be used for treating and/or preventing hyperproliferative diseases, virus-induced infectious diseases and/or cardiovascular diseases; the medicine can exert drug effect at enzyme level and cell level, and has excellent effect and IC 50 The value is optimal and can reach the nanomolar concentration level;
(3) The preparation method of the compound is simple and convenient and is easy to operate.
Drawings
FIG. 1 is a diagram of Compound I-22 1 H NMR spectrum;
FIG. 2 is a mass spectrum of Compound I-22.
Detailed Description
The technical scheme of the invention is further described below by referring to examples.
Reagent and material:
4, 7-dichloropquinazolin, N-methylpiperazine, 4-phenylpyrimidin-2-amine, 4, 5-bis-diphenylphosphine-9, 9-dimethylxanthene, (2-methoxyphenyl) boric acid, [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride is derived from Shanghai Biget medical science and technology Co, shanghai Haohong biomedical science and technology Co;
CDK9/Cyclin T1 was derived from the American Reaction Biology Corp (Malvern PA) company and MV4-11 tumor cell line was derived from Nanjing An Nakang Biotech Co.
Instrument:
1 h NMR was measured using a BRUKER AVANCE-300 nuclear magnetic resonance apparatus (Brucker, switzerland) with TMS as the internal standard and displacement value (δ) in ppm; low resolution mass spectrometry was determined using an expression compact fourier transform mass spectrometer.
Example 1: synthesis of 4- (4-methylpiperazin-1-yl) -N- (4-phenylpyrimidin-2-yl) quinazolin-7-amine (Compound I-1)
(1) Synthesis of 7-chloro-4- (4-methylpiperazin-1-yl) quinazoline (Compound B-1)
In a 50mL single-necked flask, 4, 7-dichloroquinazoline (199mg, 1.00 mmol) was added, 10mL of dichloromethane was added for dissolution, a solution of N-methylpiperazine (110 mg,1.10 mmol) and triethylamine (111 mg,1.10 mmol) in dichloromethane was slowly added, the reaction was stirred at room temperature for about 12h after the dropwise addition was completed, after the TLC monitoring was completed, the reaction solution was concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane: methanol=100:1) to obtain 234mg of pale yellow solid in 89% yield; ESI-MS m/z 263[ M+H ]] + 。
(2) Synthesis of 4- (4-methylpiperazin-1-yl) -N- (4-phenylpyrimidin-2-yl) quinazolin-7-amine (Compound I-1)
To a 25mL two-necked flask was added 4-phenylpyrimidine-2-amine (34 mg,0.20 mmol), compound B-1 (53 mg,0.20 mmol), cesium carbonate (130 mg,0.40 mmol), palladium acetate (4.5 mg,0.02 mmol) and 4, 5-bis-diphenylphosphine-9, 9-dimethylxanthene (11.5 mg,0.02 mmol), anhydrous toluene (5-10 mL) were dissolved, degassed with nitrogen, reacted under nitrogen protection at 100℃for 2-6 h by heating, the reaction solution was filtered and concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane: methanol=100:1) to give 28mg of pale yellow solid in 35% yield; 1 H NMR(300MHz,DMSO-d 6 )δ10.32(s,1H),8.51(d,J＝5.7Hz,1H),8.35(s,1H),8.23(dd,J＝8.5,0.4Hz,1H),7.95–8.06(m,2H),7.78(dd,J＝2.2,0.6Hz,1H),7.56–7.62(m,1H),7.55–7.38(m,2H),7.35(dd,J＝8.4,2.3Hz,1H),7.16(d,J＝5.6Hz,1H),3.66–3.73(m,4H),2.50–2.59(m,4H),2.26(s,3H).ESI-MS m/z:398[M+H] + 。
example 2: synthesis of N- (4- (2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (compound I-2)
(1) Synthesis of 4- (2-methoxyphenyl) pyrimidin-2-amine (compound A-1)
To a 25mL eggplant-shaped bottle was added (2-methoxyphenyl) boronic acid (502 mg,3.3 mmol), 4-chloropyrimidin-2-amine (390 mg,3.0 mmol) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (110 mg,0.15 mmol), sodium carbonate (636 mg,6.0 mmol), 1, 4-dioxane 12mL and purified water 2mL, degassing with nitrogen, heating at 100 ℃ for 6h under nitrogen protection, extracting the reaction liquid with ethyl acetate, concentrating, purifying by column chromatography (ethyl acetate: petroleum ether=1:1), and recrystallizing to obtain light yellow powder 450mg with a yield of 75%; ESI-MS m/z 202[ M+H ]] + 。
(2) Synthesis of N- (4- (2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (compound I-2)
Starting with compound A-1 (40 mg,0.20 mmol) and compound B-1 (53 mg,0.20 mmol), according to the method of example 1, 39mg of a white solid was obtained in 45% yield; 1 H NMR(300MHz,DMSO-d6)δ10.25(s,1H),8.47(d,J＝5.6Hz,1H),8.35(s,1H),8.24(dd,J＝8.5,0.5Hz,1H),7.74(dd,J＝2.3,0.5Hz,1H),7.55(dd,J＝7.8,1.3Hz,1H),7.44(d,J＝5.7Hz,1H),7.40–7.29(m,2H),7.14(td,J＝7.6,1.3Hz,1H),7.00(dd,J＝7.6,1.4Hz,1H),3.87(s,3H),3.63–3.70(m,4H),2.47–2.57(m,4H),2.37(s,3H).ESI-MS m/z:428[M+H] + 。
by operating in a similar manner to examples 1-2, the following compounds were prepared:
/>
/>
/>
/>
/>
/>
/>
example 3: inhibition of CDK9 kinase activity by Compounds
The synthesized compounds were tested for their inhibitory activity on CDK9 by HotSpotSM kinase method/Fluorescence Resonance Energy Transfer (FRET) method by the American Reaction Biology Corp. (Malvern PA), for example CDK9/Cyclin T1.
The specific operation method comprises the following steps: CDK9/Cyclin T1 was diluted to the appropriate concentration with kinase diluent for use. The kinase reaction mixture contains CDK9/Cyclin T1, peptide substrate, HEPES (pH 7.5), BRIJ-35, and MgCl 2 And EDTA. CDK9 phospho-peptide substrate was used as a 100% phosphorylation control, and no ATP was added as a 0% phosphorylation control. After 1h of reaction at room temperature, development Reagent A was added to the reaction system in moderate dilution. The reaction was continued at room temperature for 1h, sto was addedp Reagent stopped the reaction. The excitation light wavelength was 400nm, and fluorescence intensities at 445nm (coumarin) and 520nm (fluorescein) were detected. Test compound inhibition (n=2) was calculated as per the formula, IC 50 The results of the analysis are shown in Table 1, which are obtained by plotting the percent inhibition and the logarithmic concentration values.
Inhibition of CDK9 kinase Activity by Compounds of Table 1
In the table, "A" represents IC 50 The value is less than 0.1. Mu.M, and "B" represents IC 50 The value is between 0.1. Mu.M and 1. Mu.M, and "C" represents IC 50 The value is greater than 1. Mu.M.
As shown in Table 1, all compounds have inhibitory effect on CDK9 kinase activity, wherein compounds I-1, I-2, I-5, I-7-I-10, I-18-I-19, I-27, I-32 and I-38-I-40 inhibit CDK9 kinase IC 50 IC with CDK9 kinase inhibition by the remaining compounds having a value of no more than 1. Mu.M 50 Values of no more than 0.1. Mu.M can be achieved at nanomolar concentration levels.
Example 4: antiproliferative effect of compounds on tumor cells
Experimental principle: the MTT method for measuring the inhibition of leukemia cell line MV4-11 tumor cell line by MTT method and in vitro test of anti-tumor proliferation activity is a method for detecting survival and growth of cells, wherein the detection principle is that NADP related dehydrogenase (succinate dehydrogenase) in mitochondria of living cells can reduce exogenous MTT into insoluble blue purple crystalline Formazan (Formazan) and deposit in cells, and dead cells have no function. Purple crystal formazan in cells is dissolved by using dimethyl sulfoxide (DMSO) or triple solution (10% SDS-5% isobutanol-0.01 mol/L HCl), and the light absorption value (OD value) at 570nm wavelength is detected by an ELISA detector, so that the living cell quantity can be indirectly reflected.
The specific operation method comprises the following steps: inoculating tumor cells in logarithmic growth phase into 96-well culture plate according to certain cell amount, culturing for 24 hr, adding test compound (directly after suspending cell plate), and culturing at 37deg.C with 5% CO 2 After culturing for 48h or 72h, adding MTT, culturing for 4h, dissolving in DMSO, crystallizing, measuring OD value at 570nm wavelength by ELISA, and calculating inhibition rate and IC of the compound 50 Values, analytical results are shown in tables 2 and 3.
Antiproliferative effect of compounds of Table 2 on MV4-11 tumor cells
In the table, "A" represents IC 50 The value is less than 0.1. Mu.M, and "B" represents IC 50 The value is between 0.1. Mu.M and 1. Mu.M, and "C" represents IC 50 The value is greater than 1. Mu.M.
TABLE 3 inhibition of various tumor cell lines by Compounds I-12
As shown in Table 2, all of the compounds had inhibitory effect on MV4-11 tumor cells, wherein compounds I-3 to I-4, I-6, I-9, I-13, I-21, I-32 and I-38 inhibited the IC of MV4-11 tumor cells 50 IC with values not exceeding 1 mu M for inhibiting MV4-11 tumor cells by compounds I-10-I-12, I-14-I-20, I-22-I-31, I-33-I-37 and I-39-I-46 50 Values of no more than 0.1. Mu.M can be achieved at nanomolar concentration levels.
As shown in Table 3, compound I-12 has inhibitory effects on various solid organ cancers, including, but not limited to, various hematological malignancies, such as acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, burkitt's lymphoma, follicular lymphoma, and solid tumors such as breast cancer, non-small cell lung cancer, melanoma, renal cancer, ovarian cancer, prostate cancer, colon cancer, and central nervous system tumors.
In summary, the protein kinase inhibitor, the derivatives and the pharmaceutical composition thereof can be prepared into anticancer drugs, and can also be prepared into drugs for treating other diseases, including heart, virology, inflammation and pain related diseases.

Claims (7)

1. A CDK9 kinase inhibitor compound and derivatives thereof, wherein said CDK9 kinase inhibitor compound and derivatives thereof have the structure of formula (II):
wherein:
R 1 is that
R 2 Is hydrogen atom, morpholin-4-yl, piperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, homopiperazinyl, N-methylpiperazinyl, piperidinyl, (N-methylpiperazin-4-yl) piperidinyl, (tetrahydropyran-4-yl) amino, (tetrahydrofuran-3-yl) amino, (N-methylpiperidin-4-yl) amino, 2- (dimethylamino) ethylamino, 2-methoxyethylamino, 3-methoxypropylamino, 2, 5-diazabicyclo [2.2.1]]Heptyl-2-yl, 4-methylpiperazin-3-one, (S) -3-methylpiperazin, (R) -3-methylpiperazin, (8-azabicyclo [ 3.2.1)]Octane-3-yl) amino, (R) -2-methylpiperazinyl, (S) -2-methylpiperazinyl, pyrrolidinyl, (2-methoxyethyl) amino, (3-methoxypropyl) amino, (tetrahydropyran-4-yl) amino, (tetrahydrofuran-3-yl) amino, N-dimethylamino, 4-difluoropiperidinyl, (piperidin-4-yl) amino, (2-aminoethyl) amino, (2- (methylamino) ethyl) amino, (2- (dimethylamino) ethyl) (methyl) amino, (3-methoxyethyl) amino, 4-methylpiperazin-2-one;
R 3 is a hydrogen atom, a fluorine atom;
R 4 is a hydrogen atom;
R 5 is hydrogen atom, fluorine atom, methoxy, ethoxy and benzyloxy;
R 6 、R 7 is one or more hydrogen atoms, fluorine atoms, C 1 -C 3 Alkyl, methoxy;
q is an oxygen atom or an imino group.
2. The CDK9 kinase inhibitor compounds and derivatives thereof according to claim 1, wherein the CDK9 kinase inhibitor compounds and derivatives thereof have the structure:
R 1 is phenyl, 2-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-ethoxyphenyl, 4-fluoro-2-ethoxyphenyl, 2-benzyloxyphenyl, 4-fluoro-2-benzyloxyphenyl, 3-isopropyl-2-methyl-2H-indazol-5-yl, 7-fluoro-3-isopropyl-2-methyl-2H-indazol-5-yl, 1-isopropyl-2-methyl-1H-benzo [ d ]]Imidazol-6-yl, 4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ]]Imidazol-6-yl, 1-methyl-1H-indol-3-yl.
3. A CDK9 kinase inhibitor compound and derivatives thereof, wherein said CDK9 kinase inhibitor compound is any one of the following:
4- (4-methylpiperazin-1-yl) -N- (4-phenylpyrimidin-2-yl) quinazolin-7-amine (I-1),
n- (4- (2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-2),
n- (4- (4-fluoro-2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-3),
n- (5-fluoro-4- (4-fluoro-2-methoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-4),
n- (4- (2-ethoxyphenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-5),
n- (4- (2-ethoxy-4-fluorophenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-6),
n- (4- (2- (benzyloxy) phenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-7),
n- (4- (2- (benzyloxy) -4-fluorophenyl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-8),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-9),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4-morpholinylquinazolin-7-amine (I-10),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (piperazin-1-yl) quinazolin-7-amine (I-11),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-12),
4- (4-ethylpiperazin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-13),
4- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -1-methylpiperazin-2-one (I-14),
1- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -4-methylpiperazin-2-one (I-15),
(S) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (3-methylpiperazin-1-yl) quinazolin-7-amine (I-16),
(R) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (3-methylpiperazin-1-yl) quinazolin-7-amine (I-17),
(R) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (2-methylpiperazin-1-yl) quinazolin-7-amine (I-18),
(S) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (2-methylpiperazin-1-yl) quinazolin-7-amine (I-19),
4- (1, 4-homopiperazin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-20),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (4-methyl-1, 4-homopiperazin-1-yl) quinazolin-7-amine (I-21),
4- (2, 5-diazabicyclo [2.2.1] hept-2-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-22),
N 4 - (8-azabicyclo [ 3.2.1)]Octane-3-yl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-23),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (piperidin-4-yl) quinazoline-4, 7-diamine (I-24),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (1-methylpiperidin-4-yl) quinazoline-4, 7-diamine (I-25),
N 4 - (2- (dimethylamino) ethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-26),
N 4 - (2-aminoethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazoline-4, 7-diamine (I-27),
N 4 - (2- (dimethylamino) ethyl) -N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 Methyl quinazoline-4, 7-diamine (I-28),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (2- (methylamino) ethyl) quinazoline-4, 7-diamine (I-29),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (2-methoxyethyl) quinazoline-4, 7-diamine (I-30),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (3-methoxypropyl) quinazoline-4, 7-diamine (I-31),
5- (7- (((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) -2, 5-diazabicyclo [2.2.1] heptane-2-carboxylic acid ester (I-32),
n- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-33),
n- (4- (4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-34),
n- (5-fluoro-4- (4-fluoro-1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-35),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (tetrahydrofuran-3-yl) quinazolin-4, 7-diamine (I-36),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 - (tetrahydro-2H-pyran-4-yl) quinazoline-4, 7-diamine (I-37),
N 7 - (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -N 4 ,N 4 Dimethylquinazoline-4, 7-diamine (I-38),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -2-methyl-4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-39),
4- (azido-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-40),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (piperidin-1-yl) quinazolin-7-amine (I-41),
n- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) -4- (pyrrolidin-1-yl) quinazolin-7-amine (I-42),
1- (4- (7- ((4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) amino) quinazolin-4-yl) piperazin-1-yl) ethanone (I-43),
4- (4, 4-difluoropiperidin-1-yl) -N- (4- (3-isopropyl-2-methyl-2H-indazol-5-yl) pyrimidin-2-yl) quinazolin-7-amine (I-44),
n- (4- (1-isopropyl-2-methyl-1H-benzo [ d ] imidazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-45),
n- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-46),
N 4 - (2-methoxyphenyl) -N 2 - (4- (4-methylpiperazin-1-yl) quinazolin-7-yl) pyrimidine-2, 4-diamine (I-47),
n- (4- (2-methoxyphenoxy) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-48),
n- (4- (1-isopropyl-1H-benzo [ d ] [1,2,3] triazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-49),
n- (4- (1-methyl-1H-benzo [ d ] [1,2,3] triazol-6-yl) pyrimidin-2-yl) -4- (4-methylpiperazin-1-yl) quinazolin-7-amine (I-50).
4. A CDK9 kinase inhibitor compound and derivatives thereof according to any one of claims 1 to 3 wherein the pharmaceutically acceptable salt is a salt of the CDK9 kinase inhibitor with an acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.
5. A process for the preparation of a CDK9 kinase inhibitor compound and derivatives thereof according to any one of claims 1 to 4, which comprises:
the bromo-compound A0 is firstly converted into the pinacol borate A1 and then subjected to coupling reaction to obtain a compound A, or the bromo-compound A0 is directly subjected to coupling reaction to obtain the compound A; the compound B1 is alkylated to introduce R 2 Obtaining a compound B; the compound A and the compound B are subjected to alkylation reaction to obtain a compound (I);
therein, W, V, X, Y, Z, R 1 、R 2 、R 3 Is as defined in any one of claims 1 to 3;
adding the corresponding acid solution into the solution of the compound (I) prepared by the method, and removing the solvent under reduced pressure after complete salification to obtain the pharmaceutically acceptable salt of the CDK9 kinase inhibitor compound.
6. A pharmaceutical composition comprising a CDK9 kinase inhibitor compound and/or derivative thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
7. Use of a CDK9 kinase inhibitor compound and derivatives thereof according to any one of claims 1 to 4 in the preparation of a medicament for the treatment and/or prophylaxis of lung cancer, prostate cancer, cervical cancer, colorectal cancer, melanoma, ovarian cancer, breast cancer, renal cancer, tumours of the nervous system, lymphomas or leukaemias.
CN202010329894.4A 2020-04-24 2020-04-24 Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application Active CN113549018B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010329894.4A CN113549018B (en) 2020-04-24 2020-04-24 Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010329894.4A CN113549018B (en) 2020-04-24 2020-04-24 Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application

Publications (2)

Publication Number Publication Date
CN113549018A CN113549018A (en) 2021-10-26
CN113549018B true CN113549018B (en) 2024-02-27

Family

ID=78129461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010329894.4A Active CN113549018B (en) 2020-04-24 2020-04-24 Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application

Country Status (1)

Country Link
CN (1) CN113549018B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
JP2003238558A (en) * 2002-02-08 2003-08-27 Mitsui Chemicals Inc Amine compound
WO2004041810A1 (en) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
CN105503837A (en) * 2015-12-31 2016-04-20 中山大学 Substitute quinazolines derivative with Aurora kinase inhibitory activity and application thereof
KR20170134215A (en) * 2016-05-26 2017-12-06 덕산네오룩스 주식회사 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof
WO2018007648A1 (en) * 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) 4-anilino-quinoline compounds as anti-cancer agents
WO2019134969A1 (en) * 2018-01-05 2019-07-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
CN110023319A (en) * 2016-11-23 2019-07-16 株式会社Lg化学 Electroactive compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373484A1 (en) * 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN102356075B (en) * 2009-01-23 2015-06-10 里格尔药品股份有限公司 Compositions and methods for inhibition of the jak pathway
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
JP2003238558A (en) * 2002-02-08 2003-08-27 Mitsui Chemicals Inc Amine compound
WO2004041810A1 (en) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
CN105503837A (en) * 2015-12-31 2016-04-20 中山大学 Substitute quinazolines derivative with Aurora kinase inhibitory activity and application thereof
KR20170134215A (en) * 2016-05-26 2017-12-06 덕산네오룩스 주식회사 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof
CN109195950A (en) * 2016-05-26 2019-01-11 德山新勒克斯有限公司 Organic electronic element compound, organic electronic element and its electronic device using the compound
WO2018007648A1 (en) * 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) 4-anilino-quinoline compounds as anti-cancer agents
AU2017294572A1 (en) * 2016-07-08 2019-01-24 Chu De Nice 4-anilino-quinoline compounds as anti-cancer agents
CN110023319A (en) * 2016-11-23 2019-07-16 株式会社Lg化学 Electroactive compound
WO2019134969A1 (en) * 2018-01-05 2019-07-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS.《CAS RN：1349752-03-9、587023-95-8》.DATABASE REGISTRY[Online].2011,全文. *
Vladimir Pavlovic等.《Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry》.Synthetic Communications1.2009,(第39期),第4251页表1. *

Also Published As

Publication number Publication date
CN113549018A (en) 2021-10-26

Similar Documents

Publication Publication Date Title
KR102450727B1 (en) Compounds useful for inhibiting CDK7
TWI601718B (en) 2-arylaminopyridines, pyrimidine or triazine derivatives, processes for preparing the same, and uses thereof
CN108290899B (en) Substituted pyrrolopyrimidine compound and application thereof
KR102388312B1 (en) Aminopyrimidine compound, preparation method and use thereof
EP3102571B1 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
Lee et al. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors
KR20100017441A (en) N&#39;-(phenyl)-n-(morpholin-4-yl-pyridin-2-yl)-pyrimidine-2,4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
AU2019290722B2 (en) Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof
CN107266421B (en) Substituted benzimidazole derivatives
JP2018135268A (en) Novel heteroaryl amino-3-pyrazole derivative and pharmacologically acceptable salt thereof
WO2010003369A1 (en) Cyclin-dependent kinases inhibitor of baicalin organic amine derivatives, synthesis and use thereof
CN113549018B (en) Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application
CN110577514B (en) Human epidermal growth factor receptor inhibitor and preparation method and application thereof
CN110467637B (en) Bisaminyl chloropyrimidine compound containing phosphine oxide substituted aniline, preparation method and application thereof
Yan et al. Discovery of novel 2, 4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation
CN111836819A (en) Arylamine-substituted pyrrolopyrimidine compound, and preparation method and application thereof
CN106554318A (en) Deuterated diphenyl amino pyrimidine compound
Wang et al. Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors
CN113880816A (en) Piperazine-containing aminopyrimidine derivative and application thereof
CN115215848B (en) Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application
CN113801108B (en) Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application
CN111410667A (en) Novel (1,2,4) triazolo (1,5-a) pyridylphosphine oxides and use thereof
CN113880814B (en) Pyrimidine amine compound and application thereof
CN110642838B (en) EGFR inhibitor and preparation and application thereof
WO2023041071A1 (en) Egfr inhibitor, preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant